Detail page

Knowledge Web

Person

Michael Hundemer (1972-)

Arzt

Name	Michael Hundemer
Time	1972- (Date of birth and death)
Place	Heidelberg (Wirkungsort) Deutschland
Academic degree	Dr. med.
Profession	Arzt (characteristic profession)
Variant	M. Hundemer
Related	Universitätsklinikum Heidelberg. Zentrum für Innere Medizin (06/2001-) Universität Heidelberg. Medizinische Fakultät (Lehrbeauftragter) (07/2015-)
Further information	Oberarzt, Leiter der klinischen Einheit Durchflusszytometrie und des Labors für Zelltherapie am Universitätsklinikum Heidelberg, Medizinische Klinik, Innere Medizin V, Hämatologie, Onkologie, Rheumatologie
Record type	Person
GND-Identifier	128390549
Record ID	128390549
Involved in show all The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities CD8+ CD28− regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) The Effect of Elotuzumab on T cells in Patients with Multiple Myeloma Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) Selective elimination of immunosuppressive T cells in patients with multiple myeloma Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients Combined Immunohistochemistry after Mass Spectrometry Imaging for Superior Spatial Information Cell-based immunotherapy approaches for multiple myeloma IL-10 inducible CD8+ regulatory T-cells are enriched in patients with multiple myeloma and impact the generation of antigen-specific T-cells Immunregulatorische Aktivität CD8+CD28- T-Lymphozyten im Zellkulturmodell mit einem Tumor-assoziiertem Antigen des Multiplen Myeloms Platelet Count before Peripheral Blood Stem Cell Mobilization Is Associated with the Need for Plerixafor But Not with the Collection Result Active but not inactive granulomatosis with polyangiitis is associated with decreased and phenotypically and functionally altered CD56dim natural killer cells Peripheral blood natural killer cell percentages in granulomatosis with polyangiitis correlate with disease inactivity and stage Human cytomegalovirus infection of tumor cells downregulates NCAM (CD56): a novel mechanism for virus-induced tumor invasiveness In-vitro-Untersuchungen zum Metastasierungsverhalten humaner Neuroblastomzellinien

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Michael Hundemer (1972-)

The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities

CD8+ CD28− regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study

Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD

Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)

The Effect of Elotuzumab on T cells in Patients with Multiple Myeloma

Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)

Selective elimination of immunosuppressive T cells in patients with multiple myeloma

Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma

Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients

Combined Immunohistochemistry after Mass Spectrometry Imaging for Superior Spatial Information

Cell-based immunotherapy approaches for multiple myeloma

IL-10 inducible CD8+ regulatory T-cells are enriched in patients with multiple myeloma and impact the generation of antigen-specific T-cells

Immunregulatorische Aktivität CD8+CD28- T-Lymphozyten im Zellkulturmodell mit einem Tumor-assoziiertem Antigen des Multiplen Myeloms

Platelet Count before Peripheral Blood Stem Cell Mobilization Is Associated with the Need for Plerixafor But Not with the Collection Result

Active but not inactive granulomatosis with polyangiitis is associated with decreased and phenotypically and functionally altered CD56dim natural killer cells

Peripheral blood natural killer cell percentages in granulomatosis with polyangiitis correlate with disease inactivity and stage

Human cytomegalovirus infection of tumor cells downregulates NCAM (CD56): a novel mechanism for virus-induced tumor invasiveness

In-vitro-Untersuchungen zum Metastasierungsverhalten humaner Neuroblastomzellinien